Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – PRNewswire
/PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg……
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Parkville, Victoria. Vosoritide…
-
Business22 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General23 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News9 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General22 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts